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Introduction
Sweet’s syndrome (SS) is an uncommon disease of not enti-
rely understood pathophysiology. Depending on the clinical 
context, it can be classified into classic SS, malignancy-
-associated SS (MASS) and drug-induced SS (DISS) [1]. The
classic variant is the most frequent, accounting for more
than 50% of cases. On average, 20% of SS patients have an
underlying malignancy, and 10% belong to the drug-induced
subtype (DISS) [1]. Since prognosis depends on comorbid
conditions, it is essential to establish a proper diagnosis.
Case report
A 73-year-old patient was referred to our clinic because 
of an almost 3-year history of recurrent bouts of tender 
papulo-nodules and plaques. Two skin biopsies performed 
earlier (2014) had described lymphocytic perivascular 
infiltrates. He was diagnosed as having cutaneous lupus 
erythematosus and was treated with methylprednisolone 
at daily doses ranging from 16 to 32 mg. Initially, there 
was a prompt clinical response and long-lasting remission. 
Unfortunately, over time the disease became increasingly 
severe with multiple relapses and reduced symptom-free 
intervals. He received hydroxychloroquine at a dose of 
200 mg per day but with no improvement. On admission, 
the patient presented with widespread nodules and plaqu-
es with targetoid-appearance (Figure 1). There were also 
aphthous-like ulcers on the oral mucosa (Figure 2).
Figure 1. Widespread nodules and plaques with targetoid- 
-appearance
Figure 2. Aphthous-like ulcers on the oral mucosa
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While disease flared, findings from laboratory tests 
showed an elevated erythrocyte sedimentation rate 
(ESR): 120/h and C-reactive protein (0–5 mg/L): 78.4– 
–137.1 mg/L. During a one-year observation period, repe-
ated blood tests revealed a tendency towards anemia, and 
leukopenia with neutropenia (Table I). Interestingly, besi-
des such laboratory peculiarities (leukopenia with neu-
tropenia), only a few exacerbations were accompanied by 
raised temperature. Tumor markers and electrophoresis 
were within normal values. Screening for autoimmune 
diseases (ANAs, ENAs, anti-double-stranded DNA, anticar-
diolipin antibodies, c-ANCAs, p-ANCAs) yielded negative 
results. Serological tests for Yersiniosis anti-Yersinia en-
terocolitica IgA, IgG antibodies were negative. Neither ab-
dominal not chest computed tomography scans were re-
markable. Results of gastroscopy and colonoscopy were 
also inconspicuous. We performed two consecutive skin 
biopsies (2016, 2017) showing dermal infiltrates composed 
mainly of neutrophils, eosinophils, and myeloid cells (Figu-
res 3A, B): lesional infiltrate labeled with myeloperoxidase 
and CD15 (polymorphonuclear neutrophils) and CD68 (my-
eloid cells). There was also some admixture of T lymphocytes 
(CD45+ CD3+) (Figure 3C).
Our patient met the criteria for SS. He had both ma-
jor criteria (clinical manifestations, neutrophilic infiltrate 
without leucocytoclasia) and two minor criteria (associa-
ted disease, response to corticosteroid therapy). Because 
of the chronic, recurrent course and atypical clinical and 
laboratory features, the diagnostic work-up was broade-
ned to include bone marrow aspirate smear and trephine 
biopsy. Bone marrow aspirate showed dysplasia of 10% of 
myeloid lineage cells (Figure 3D), whereas trephine biop-
sy revealed hypercellularity and features of multilineage 
dysplasia. Cytogenetic examination of bone marrow found 
normal karyotype. Later, based on the investigations abo-
ve and laboratory parameters, MDS with multilineage dys-
plasia (MDS-MLD) was diagnosed.
Initially, we started him on oral prednisone 0.5 mg/kg/ 
/day, with a good clinical response. Unfortunately, there 
were flares of SS on doses below 20 mg per day. Then, dap-
sone (100 mg/day) was added for three months, but with 
no benefit. Finally, we decided to give our patient 100 mg 
thalidomide/day along with a prophylactic dose of acetylsa-
licylic acid. Thalidomide (TH) led to complete resolution of 
the disease, and allowed for tapering and finally stopping 
steroids within one month. Due to somnolence and con-
stipation, we had to reduce the dose to 50 mg/day after 
two months. During the whole observation period, we did 
not observe any adverse events. Importantly, TH also sta-
bilized the patient’s blood morphology. Nevertheless, we 
were unable to discontinue the TH because of recurrences 
of skin eruption. Currently, he is still on 25 mg of thalido-
mide every other day, which controls the disease (Table I).
Discussion
Sweet’s syndrome (acute febrile neutrophilic dermatosis) 
belongs to a heterogeneous group of neutrophilic der-
matoses (NDs), which are characterized by histologically 
evidenced neutrophilic infiltrate [2]. Hematologic disorders 
account for 85% of MASS. The most prevalent are acute 
myeloid leukemia (AML) and myelodysplastic syndromes 
(MDS) [3]. The less frequently reported ones are myeloproli-
ferative diseases, CLL, and paraproteinemias. Solid tumors 
constitute 7–15% of associated cancers [1]. Myelodyspla-
stic syndromes are a group of clonal hematopoietic stem 
Table I. Patient’s blood morphology during the curse of the disease
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Thalidomide – – – – 100 mg/d 50 mg/d 25 mg/d 50 mg/d 25 mg/d 25 mg/d
Hb [dL] 10.7 10.8 13.6 13.2 12.6 12.8 13.7 13.3
WBC [G/L] 3.63 7.77 7.97 5.71 6.46 4.96 5.45 4.88
ANC [G/L] 1.64 5.0 6.27 3.08 3.45 1.88 3.93 2.03
PLT [G/L] 148 241 176 208 192 209 153 153
*Detailed description in the text; IBD — inflammatory bowel disease; MDS-MLD — myelodysplastic syndrome with multilineage dysplasia; Hb — hemoglobin; WBC — white blood cells; ANC — absolute neutro-
phil count; PLT — platelets
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cell diseases with cytopenia(s) and dysplastic features in 
one or more myeloid lineage [4].
Our patient presented with lesions of widespread distri-
bution (Figure 1), which is considered by some authors to 
be a potential sign of underlying malignancy [1]. Notably, 
crops of cutaneous lesions were accompanied by oral ul-
cerations (Figure 2), which are not only extremely rare in 
SS but also possibly indicative of MASS [5]. Malaise and 
low-grade fever parallelled the exacerbations, but without 
arthralgias or other constitutional symptoms. Lack of joint 
complaints and afebrile disease have both been found to 
be more prevalent in the paraneoplastic variant [6]. Unfor-
tunately, besides anemia, only a few findings have been 
consistently reported to differ between cancer-associated 
SS and the classic idiopathic form [2]. Data from case se-
ries indicates, however, that a combination of chronicity 
and refractoriness to treatment [7] plus initially lymphocy-
tic infiltrates on skin biopsy, especially in older males, co-
uld potentially indicate a distinct group of SS patients at 
higher risk of developing MDS [8, 9]. Clearly, in our case, 
there was gradually increasing anemia, and the disease 
had a chronic, remittent course. Moreover, the first biopsies 
showed predominantly lymphocytic infiltrate. Our findings 
seem to parallel observations from published case series, 
which have described ‘initial’ lymphocytic and ‘late’ neu-
trophilic patterns [8].
Many studies have revealed a strong association be-
tween myelodysplasia and autoimmune and inflammatory 
conditions (AIMs) [10]. AIMs can appear before, during, or 
after the diagnosis of MDS [10]. In the lymphocytic variant 
of MDS-associated SS, cutaneous disease has been found 
to appear between 6 months and 8 years (median 3.5 ye-
ars) [8, 9] before myelodysplastic syndrome. Patients with 
typical histopathology described by Kulasekararaj et al. [7] 
had MDS diagnosed at a median of 1.5 years following the 
development of SS.
Our findings are in agreement with previous studies in 
showing that skin lesions of SS can precede by months, 
or years, a diagnosis of MDS. In the presented patient, it 
was three years from the beginning of the SS to the con-
firmation of MDS.
The pathogenesis of SS is complex and multifactorial. 
Recent research has revealed that neutrophil-rich cutaneo-
us inflammation might be a consequence of an overactive 
Figure 3A, B. Infiltration of the skin composed of neutrophils, eosinophils and myeloid cells; C. The lesional infiltrate showing positive im-
munostaining for CD68; D. Myelodysplastic syndrome with multilineage dysplasia in trephine biopsy of patients with Sweet’s syndrome
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innate immune system [11] and excessive synthesis of in-
terleukin 1 (IL-1) family members [12, 13]. Paraneoplastic 
inflammation implicated in MDS includes abnormal expres-
sion of distinct inflammatory cytokines and chemokines, 
which are produced by the immune, stromal, and malignant 
cells. There are also qualitative and quantitative differences 
in inflammatory cell recruitment [14]. Remarkably aberrant 
innate immune activation (specifically, NLRP3 inflammaso-
me formation and pyroptosis) is now believed also to be 
a key driver of ineffective hematopoiesis in MDS [15]. In 
the setting of cancer-associated Sweet syndrome, the un-
derlying myeloid dysfunction may disrupt networks of cyto-
kine and stimulating factors, which in turn could exaggerate 
neutrophil chemotaxis and activation [16].
Thalidomide and its derivates belong to a group of 
therapeutic agents collectively called immunomodulato-
ry drugs (IMIDs). Research carried out in recent years has 
identified the anti-proliferative, anti-angiogenic, and im-
munomodulatory potential of IMIDs [17]. Modulation of 
the immune system may be the primary mode of action of 
thalidomide in SS. Thalidomide may act via modulation of 
cytokine secretion. For example, it is best known for the 
downregulation of tumor necrosis factor alpha. TH may 
also decrease levels of IL-1, IL-6 [18] via inhibition of the 
caspase-1-NLRP3 inflammasome axis [19, 20]. Studies 
suggest that TH affects neutrophil chemotaxis and inhibits 
granulocyte-mediated tissue injury [21, 22]. Inhibition of 
phagocytosis and reduced expression of matrix metallo-
proteinases (MMP) may also translate into the efficacy of 
TH in ND [16, 18, 23].
Only a handful of reports have described the use of tha-
lidomide in SS [8, 24]. It has mainly been used in patients 
with the hemopathy-associated form because of steroid-
-dependency or refractoriness to other drugs. In the vast 
majority of cases, it shows high effectiveness. Unfortuna-
tely, despite an excellent response, TH also causes a high 
drop-out rate due to adverse events.
Two important observations emerge from our case. 
Firstly, knowledge of the specific phenotype of hemopathy-
-associated SS prompted us to closely and regularly mo-
nitor the patient and then introduce increasingly invasive 
procedures (trephine biopsy) when blood parameters just 
reached the threshold considered to be diagnostic for MDS. 
Secondly, it is increasingly acknowledged that MDS and au-
toimmune and inflammatory diseases (AIDs) are intercon-
nected and reciprocally influence each other [25]. Due to 
substantial cross-talk between the mediators and cytoki-
nes in the local tumor microenvironment and systemic cir-
culation, it is plausible to assume that targeting of cancer-
-related inflammation has the potential to affect both the 
underlying neoplasm and the associated skin disease [26].
We believe that thalidomide, at its lowest but effecti-
ve dose, allowed for control of both diseases without any 
adverse events. Notably, 25 mg daily dosing of TH has 
been considered relatively safe in respect to neuropathy 
[27]. Another point is that even low or ultra-low doses of 
thalidomide could be a valuable option in anemic MDS 
patients [28].
Conclusions
The presented case emphasizes the importance of inclu-
ding myelodysplastic syndrome into the diagnostic work-up 
in patients with SS. While most patients with SS respond to 
corticosteroid therapy, treatment of the disease in the set-
ting of myeloid malignancy can be challenging, with a high 
incidence of steroid dependence and relapse. Thalidomide 
should be considered as an alternative, third-line agent in 
the treatment of such patients.
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